Abstract 287P
Background
Yoga is one of the oldest therapies and has been practiced for millennia to promote physical and mental health. Yoga decreased cancer-related symptoms and treatment-related adverse effects, such as fatigue and nausea, and enhanced general well-being and quality of life. However, the duration of the yoga intervention in these investigations was a maximum of six months. In this study, the yoga intervention was given for one year.
Methods
The institutional ethics committee approved the study. This study enrolled a total of 96 patients after considering the inclusion and exclusion criteria, and they were randomly divided into two groups (non-yoga and yoga). Patients received training for the asanas Tadasna, Tiryaka Tadasana, Katichakrasana, Padadhirasana, Gomukhasana, Shavasana, Nadishodhan Pranayama, and Ujjayi Pranayama, which were performed for 45 minutes, five days per week, for the period of one year. We used the validated EORTC-QLQ30 and EORTC-BR23 questionnaires to assess the quality of life, symptomatic scale, fatigue, and functional scale in breast cancer patients. We calculated them at baseline, the fourth month, the eighth month, and the twelfth month, and compared them to the control group as well as with the intergroup.
Results
For each time point, 42 patients in the yoga group and 40 patients in the control group were analyzed. In the yoga group, two patients died and four were lost to follow-up and in non-yoga group, four patients died and four were lost to follow-up. At 4th(p<.05), 8th (p<0.01), and 12th month (p<0.001) post-baseline, the yoga group's quality of life improved significantly. In contrast, the non-yoga group shows substantial declines from baseline to the 4th(p<.05), 8th (p<0.01), and 12th month (p<0.001). The symptomatic and functional scales are also enhanced in the yoga group relative to the control group. The most significant difference from baseline was found in the functional scale at 12 months (p<0.05).
Conclusions
Long-term yoga intervention improved both their functional and symptomatic scales, as well as their quality of life. This suggests that yoga could be an effective complementary therapy for breast cancer patients undergoing treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Ayush, Government of India.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
293P - Generic dabigatran for cancer-associated venous thromboembolism: Real-world data
Presenter: Fen Saj
Session: Poster viewing 04
294P - Cross-sectional analysis on cancer-related distress, belief in alternative medicine among cancer patients and attendants visiting a tertiary care center in Northern India
Presenter: Amit Sehrawat
Session: Poster viewing 04
296P - Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Presenter: Yi-Long Wu
Session: Poster viewing 04
297P - Transbronchial microwave ablation of early lung cancers and lung oligometastases: Mid-term results
Presenter: Joyce Chan
Session: Poster viewing 04
298P - Does trisegmentectomy have functional benefit over lobectomy? Comparative analysis of changes in lung function and volumetry among stage IA non-small cell lung cancer patients
Presenter: sumin shin
Session: Poster viewing 04
299P - Furmonertinib as adjuvant therapy in EGFR-mutated non-small cell lung cancer following radical lung cancer surgery
Presenter: Qingyi Zhang
Session: Poster viewing 04
300P - Real-world efficacy and safety of anlotinib in combination with PD-1/PD-L1 inhibitors as first-line or second-line treatment in advanced non-small cell lung cancer
Presenter: Xin Shang
Session: Poster viewing 04
301P - Oxygen desaturation during 6-min walk test: Implications for postoperative complications in non-small cell lung cancer patients with impaired lung function
Presenter: Hye Yun Park
Session: Poster viewing 04
302P - Treatment patterns in resectable early-stage NSCLC in Taiwan: Subgroup analysis of a global real-world study
Presenter: Jin-Yuan Shih
Session: Poster viewing 04